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In the past, systolic dysfunction was believed to be the
predominant cause of heart failure (HF). That concept is
no longer tenable, because in the United States and else-
where, at least half of the HF population has a normal or
near-normal left ventricular ejection fraction (LVEF). Even
more striking is the observation that the percent of patients
with heart failure with preserved ejection fraction (HFpEF)
appears to be increasing in relation to the percent that have
heart failure with reduced ejection fraction (HFrEF) (1).See page 2817The reason for this shift in the ratio between HFpEF and
HFrEF is related to differences in etiologies of these con-
ditions. Although the underlying causes of HFpEF have yet
to be fully delineated, changes in the diastolic properties of
the heart that occur with aging are clearly involved (2). Thus,
as the mean age of the population increases, HFpEF will
become more common. In contrast, greater availability of
therapeutic interventions that limit myocardial damage
(particularly, in the setting of an acute myocardial infarction)
should reduce the incidence of HFrEF. As a result, HFpEF
will emerge as the predominant form of HF throughout the
world in the not too distant future.
Over the past 5 decades, effective treatments for HFrEF
have become available, and when used appropriately, they
improve the clinical course of the disease. For patients with
HFpEF, however, there has been little progress in developing
new treatments, and no therapy to date has been shown to
alter the natural history of the condition. Although the
disparity in efﬁcacy of treatments between HFrEF and
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disclose.that drugs and devices that favorably alter outcomes in
HFrEF patients are directed toward critical pathophysiolog-
ical targets that are common in this study group. In contrast,
identiﬁcation of universally relevant targets in the HFpEF
patient group has been elusive. The fact that strategies that
have proven to be highly effective in treating HFrEF patients
(e.g., neurohormonal blocking agents) have failed to produce
similar favorable results in the HFpEF group indicates
fundamental differences between these conditions.
The dichotomy in progress in developing treatments for
HFrEF and HFpEF and the absence of a clearly deﬁnable
common disease pathway for HFpEF suggest that hetero-
geneity in the underlying pathophysiological mechanisms
strongly inﬂuence an individual patient’s clinical course and
their response to treatment. This theory further implies that
by identifying a speciﬁc pathway that either results in the
development of HFpEF or strongly inﬂuences the subse-
quent clinical course, therapeutic strategies that successfully
correct the underlying abnormality would favorably affect
the natural history of the disease. In this issue of the Journal,
Hwang et al. (3) explore the implications of the presence of
coronary artery disease (CAD) in HFpEF patients. Using
the extensive Mayo clinic database, these investigators
identiﬁed 376 HFpEF patients who underwent coronary
angiography at their institution. They found that approxi-
mately two-thirds of these patients had CAD (deﬁned as
>50% stenosis). The patients with CAD had greater dete-
rioration in ventricular function and increased mortality
during follow-up compared with patients without signiﬁcant
coronary lesions. Moreover, the CAD patients who were
revascularized (either percutaneously or surgically) had
improved outcomes compared with patients who were not
revascularized. These ﬁndings persisted even after adjusting
for other variables that were likely to inﬂuence outcomes.
The investigators concluded that the natural history of
HFpEF patients with CAD differs from those without
CAD, and that patients should be categorized on the basis
of whether CAD is present.
Hwang et al. (3) are to be congratulated for their rigorous
analysis. Their work should help focus attention on the issue
of CAD in the HFpEF patient group and alert clinicians to
the need to carefully assess their HFpEF patients for the
presence and severity of CAD. The latter, however, may
prove more difﬁcult than imagined, because the investigators
also reported that neither symptoms nor stress testing were
highly predictive in this population. Overall, approximately
one-third of HFpEF patients with and without CAD had
angina symptoms, and both false negative and positive re-
sults from ischemia testing were common, even when the
more stringent criteria of >70% stenosis was used for
identifying signiﬁcant CAD. The predictive values of both
angina and stress testing in detecting CAD in a comparable
non-HF study group from the investigator’s institution
would be of interest in trying to put these ﬁndings into
context and to help determine whether making the diagnosis
of CAD is really more difﬁcult in HFpEF patients than in
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2829other groups of elderly patients. The patients with CAD,
however, did differ somewhat from the rest of the popula-
tion in that they tended to be older, had more risk factors,
were receiving more ischemic treatments, and in some cases,
had undergone revascularization procedures. Although none
of these parameters alone could be used to deﬁne the pres-
ence or absence of CAD, the cumulative proﬁle indicates
that clues in the patient’s history can help clinicians decide
whether or not to proceed with angiography or other tests to
detect CAD in a HFpEF patient.
This current study is not the ﬁrst to assess the prevalence
and impact of CAD in HFpEF patients, and as noted by
the investigators, the prevalence of CAD in their HFpEF
patient group was higher than that in other surveys (1,4,5).
This difference can be attributed to the requirement for
coronary angiography for inclusion in the current analysis.
Previous reports that did not systematically evaluate CAD,
however, might have underestimated its prevalence in the
patient groups studied. Nonetheless, the picture that
emerges is that CAD is fairly common in HFpEF patients,
and that its presence strongly inﬂuences the clinical course.
There was signiﬁcantly greater deterioration in LVEF in
patients with CAD than in those without signiﬁcant CAD,
a ﬁnding that could be only partially explained by an
intercurrent myocardial infarction. The mean reduction in
LVEF (4.6  10.3% in the CAD patients vs. 1.0  8.7% in
patients without CAD), however, did not appear to be of
sufﬁcient magnitude to explain the differences in clinical
course that were observed in this study. The fact that follow-
up LVEF measurements were obtained in only 218 of the
376 (58%) patients might have affected this result. None-
theless, as shown in Figure 3 of the study by Hwang et al.
(3), a substantially greater proportion of the CAD group
experienced a reduction in LVEF to <0.50, and in some
patients, this reduction was quite profound. In addition, the
presence of signiﬁcant CAD emerged as a signiﬁcant risk
factor for mortality, an effect that persisted in multivariate
analysis that incorporated other univariate predictors.
Although these results strongly supported an adverse impact
of CAD on the clinical course of HFpEF patients, they pro-
vided little insight into the mechanism involved. In addition
to an effect on systolic function, the potential mechanisms
included the possibility that CAD predisposed patients to
lethal ventricular arrhythmias or that it affected diastolic
properties of the left ventricle by either directly impairing
cardiomyocyte relaxation or by altering the amount (or
composition) of the interstitial matrix of the heart.
The most intriguing (and problematic) aspect of this
study was the information about the effects of revasculari-
zation on cardiac function and outcomes. Of the 255
HFpEF patients who were studied, 205 (80%) underwent
revascularization done either percutaneously (63%) or sur-
gically (37%). Repeat echocardiographic evaluation done on
a subset of 60% of these patients showed a greater reduction
in LVEF in patients who were not completely revascularized
compared with those who were. In addition, the patientswho were completely revascularized experienced signiﬁcantly
better survival than did patients who were not completely
revascularized. Although these ﬁndings suggest a highly
favorable and clinically relevant effect of revascularization in
HFpEF patients with substantial CAD, it is important to
note that there were no pre-deﬁned criteria for intervention.
Despite similarities in reported variables at the time of initial
evaluation between patients who underwent revasculariza-
tion and those who did not, the possibility of selection bias
looms heavily over these ﬁndings. Thus, the role of revas-
cularization in the HFpEF patient group remains uncertain,
and recommendations for proceeding with either percuta-
neous or surgical intervention still must depend on existing
guidelines for management of CAD, regardless of the
presence of HFpEF.
So what are the implications of this study? The data help
emphasize that although CAD is common in the HFpEF
patient group, it is difﬁcult to accurately detect by either
symptoms or stress testing. Thus, new strategies are needed
to help diagnose CAD in the HFpEF group. Although
CAD appeared to adversely affect outcomes, the mechanism
involved is far from certain, and further research to identify
the mechanisms by which CAD alters the natural history
of HFpEF is needed. Despite the encouraging results of
the current study, further research is also needed to deter-
mine whether revascularization favorably affects outcomes
in HFpEF patients and which segments (if any) of this
rapidly growing elderly patient group with numerous co-
morbid conditions would most likely beneﬁt from either
surgical or percutaneous interventions.
An argument for classifying HFpEF patients according
to the presence of CAD can be made on the basis of the fact
that CAD is common in this patient group; it appears to
alter the clinical course, and it presents a therapeutic target
for a disease for which no currently available treatments are
known to affect long-term outcome. Uncertainty about the
magnitude of the effect of CAD on outcomes, the mecha-
nisms involved, and the lack of deﬁnitive evidence that
revascularization alters the clinical course, however, suggests
that a new taxonomy on the basis of the presence of CAD
should be approached cautiously. Rather, as with hyper-
tension or atrial ﬁbrillation, both of which occur commonly
in this study group, CAD should be considered an impor-
tant co-morbidity that can affect the clinical course of
HFpEF patients. This approach would help maintain focus
on the HF component of the patient’s illness without
detracting from the need for diagnosing and treating CAD.
It is worth noting that although testing for CAD is often
rigorously pursued as part of the evaluation of HFrEF pa-
tients, this may not be the case in the HFpEF patient group.
There is evidence that quality measures such as discharge
instructions and control of blood pressure are less likely to be
pursued in HFpEF compared with HFrEF patients, and
that elderly HF patients (most of who have HFpEF) are less
likely to see a cardiologist, have an echocardiogram per-
formed, or even receive discharge counseling (6,7). Thus,
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2830although greater attention to the presence of CAD in
HFpEF patients is warranted, it appears that a substantial
change in existing practice patterns would be required for
this to occur.
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